Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hyperoside exhibits anticancer activity in non‑small cell lung cancer cells with T790M mutations by upregulating FoxO1 via CCAT1.

Oncology reports - 1 Feb 2020

Hu Zhiyuan, Zhao Pengjun, Xu Huifang

Abstract excerpt

Acquired epidermal growth factor receptor (EGFR) T790M mutation is the most common mechanism that accounts for EGFR‑TKI (tyrosine kinase inhibitor) resistance of non‑small cell lung cancer (NSCLC). High expense and acquired resistance weaken support for the use of osimertinib for T790M‑positive NSCLC treatment, and limit the efficacy and application of this drug. Hyperoside, a flavonol glycoside compound,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cell Survival
Share to Forkhead Box Protein O1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Quercetin

Share to RNA, Long Noncoding

Share to Up-Regulation

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 31894285
DOI: 10.3892/or.2019.7440

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hyperoside exhibits anticancer activity in non‑small cell lung cancer cells with T790M mutations by upregulating FoxO1 via CCAT1.PMID 31894285Read ↗

Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancerSemantic proximity Read ↗

Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization.Semantic proximity Read ↗

Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway.Semantic proximity Read ↗

Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin.Semantic proximity Read ↗

Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models.Semantic proximity Read ↗

The in Vitro and in Vivo Antitumor Effect Associating With the Hippo-yap Signaling Pathway of Gallic Acid and Its Combination With Icotinib Hydrochloride on the Non-small Cell Lung Cancer Cellular and Xenograft Tumor-bearing Nude Mouse ModelsSemantic proximity Read ↗

Sestrin-3 modulation is essential for therapeutic efficacy of cucurbitacin B in lung cancer cells.Semantic proximity Read ↗

Coccinic acid exhibits anti-tumor efficacy against NSCLC harboring EGFR L858R/T790M mutation via the EGFR/STAT3 pathway.Semantic proximity Read ↗

Combined treatment with Epimedium koreanum Nakai extract and gefitinib overcomes drug resistance caused by T790M mutation in non-small cell lung cancer cells.Semantic proximity Read ↗

Gallic acid enhances the antitumor activity of Icotinib hydrochloride in non-small cell lung cancer via of Hippo-YAP signaling pathway in vitro and in vivoSemantic proximity Read ↗

Taxus chinensis var. mairei (Lemée et Lévl) Cheng et L.K. Fu overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer via suppression of ERK1/2-related cholesterol biosynthesis.Semantic proximity Read ↗

Panduratin A from Boesenbergia rotunda Effectively Inhibits EGFR/STAT3/Akt Signaling Pathways, Inducing Apoptosis in NSCLC Cells with Wild-Type and T790M Mutations in EGFRSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.